ReviewInternational journal of clinical pharmacy2018
Pharmacovigilance in China: development and challenges.
Review in International journal of clinical pharmacy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Observational
- A Snapshot on Clinical Trials on Zotarolimus DES: A Repurposing Drug against Myocardial Infarction.The International journal of angiology : official publication of the International College of Angiology, Inc · 2025Review
- Evaluating the effectiveness of AI-enhanced "One Body, Two Wings" pharmacovigilance models in China: a nationwide survey on medication safety and risk management.Frontiers in health services · 2025Article
- Knowledge, attitude, and practice regarding pharmacovigilance among hospital pharmacists in China.Therapeutic advances in drug safety · 2025Article
- Community pharmacy professionals' knowledge, attitudes, and practices toward substandard and falsified medicines and associated factors in Bahir Dar City, Northwest Ethiopia.Frontiers in pharmacology · 2025Article
- Impact and implications of national centralized drug procurement in China.International journal of clinical pharmacy · 2024Article
- Article
- Diverse pharmacovigilance jurisdiction-The right way for global drug safety?European journal of clinical pharmacology · 2024Review
- Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials.Journal of pharmaceutical health care and sciences · 2024Article
- Exploring the influencing factors of adverse drug reaction reporting among medical personnel: a COM-B model-based study.Journal of pharmaceutical policy and practice · 2024Article
- Cross-sectional study of pharmacovigilance knowledge, attitudes, and practices based on structural equation modeling and network analysis: a case study of healthcare personnel and the public in Yunnan Province.Frontiers in public health · 2024Article
- Current career situations of Chinese pharmacovigilance professionals working for pharmaceutical companies: an exploratory survey.BMC health services research · 2023Article
- Pharmacovigilance in China: Evolution and future challenges.British journal of clinical pharmacology · 2023Review
- The effect of clinical pharmacists' intervention in adverse drug reaction reporting: a retrospective analysis with a 9-year interrupted time series.BMC health services research · 2022Article
- Safety-Related Drug Withdrawals in China Between 1999 and 2021: A Systematic Investigation and Analysis.Drug safety · 2022Article
- Artificial Intelligence-Based Pharmacovigilance in the Setting of Limited Resources.Drug safety · 2022Review
- A cross-sectional study: comparison of public perceptions of adverse drug reaction reporting and monitoring in eastern and western China.BMC health services research · 2022Article
- Knowledge, Attitude and Practice of Hospital Pharmacists in Central China Towards Adverse Drug Reaction Reporting: A Multicenter Cross-Sectional Study.Frontiers in pharmacology · 2022Article
- Detection of Drug-Induced Thrombocytopenia Signals in Children Using Routine Electronic Medical Records.Frontiers in pharmacology · 2021Article
- Overuse of intravenous infusions in China: focusing on management platform and cultural problems.International journal of clinical pharmacy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Rational drug use and drug safety are becoming increasingly important concerns in China with the increasing public access to drugs and the health-care system, and this has led to the development of pharmacovigilance in China. Aim of the review To provide a brief introduction about pharmacovigilance in China in terms of system development, utilization and challenges. Method Relevant studies on pharmacovigilance related to the study aim was undertaken through literature search to synthesize the extracted data. Results The creation and evolvement of China's pharmacovigilance system spans across 30 years since 1989. The system consists of four progressing administrative layers: county, municipal, provincial and national levels. China has passed over 20 laws and regulations related to pharmacovigilance covering the processes of drug development, manufacture, distribution and use with the aim to guard drug safety. An online spontaneous self-reporting Adverse Drug Reaction (ADR) Monitoring System was established in 2003. ADRs are mainly reported by medical institutions, pharmaceutical manufacturers, and drug distributors. Currently there is no mandatory ADR reporting requirement for pharmaceutical manufacturers, and a proposed regulation under public comment will likely change this. China has started to build active pharmacovigilance surveillance programs in addition to the passive ADR reporting system. The China Food and Drug Administration has established the intensive Safety Monitoring Program and the National Adverse Drug Reaction Monitoring Sentinel Alliance Program based on electronic health records to further the efforts of ADR reporting, monitoring and analysis. Conclusion The practice of ADR monitoring and pharmacovigilance in China have made great progress. More efforts are needed both in system building, and creation of laws and regulations to strengthen the safe use of medicines.
Indexed as
Identifiers
30051225What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.